Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

tial thrombosis increases the relative risk of death by five- to ten-fold for PNH patients.(3,7) Thrombosis is related to hemolysis in patients with PNH, and patients with both smaller and larger PNH clones are reported to experience this complication.(8,9,10,11,12) Research involving a small group of PNH patients, including those without a history of blood transfusion, found that 60 percent had sub-clinical thrombosis, which could later develop into blood clots.(13)

"For decades, people with PNH have lived with debilitating symptoms, including the threat of blood clots and their complications," said Leonard Bell, MD, Chief Executive Officer of Alexion. "This publication reinforces the importance of our goal to ensure that every PNH patient who can benefit from Soliris will have access to it."

"Many PNH patients face not only devastating symptoms, but a sharply increased risk for developing life-threatening blood clots as a result of their disease," said John Huber, Executive Director of the Aplastic Anemia & MDS International Foundation. "This news provides additional hope for patients struggling with PNH and the danger of PNH-related blood clots. We look forward to seeing the impact this new analysis has on treatment of patients with PNH."

Clinical Data

The publication, titled "Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria," analyzed data from 195 patients studied in the Soliris Phase II and Phase III trials, including the TRIUMPH and SHEPHERD studies. Patients were enrolled in the United States, Europe, Australia and Canada and treated with Soliris for up to 54 months. Soliris reduced hemolysis in all treated patients and reduced thrombosis by 92 percent, with three events during Soliris treatment compared to 39 events during the same period of time prior to treatment (P<0.0001). The collection of thrombotic events was defined prospectively by clinical trial protocols.
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Array BioPharma Inc. (Nasdaq:   ARRY) ... quarter and full year of fiscal 2014 ... those results on Tuesday, August 12, 2014.  ... Michael Carruthers , Chief Financial Officer will ... 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) 619-6397Pass Code: ...
(Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
(Date:7/28/2014)... -- ResMed (NYSE: RMD ), an innovator and ... breathing and other chronic respiratory conditions, has won a ... Taiwanese medical device manufacturer APEX Medical Corp. (APEX), prohibiting ... and 220 masks.  The judgment was entered by the ... is appealable, and applies throughout Germany.  ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
... April 17, 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. ... conducted Phase 2 clinical trials,of GVAX immunotherapy ... patients with advanced prostate cancer from these,studies ... responses to a broad array of prostate ...
... A 9-month, randomized,double-blind, parallel-group Phase II study of ... given daily to the currently,approved COPAXONE(R) 20 mg ... disease activity as measured by magnetic,resonance images (MRI) ... mg experienced a reduced mean on-trial relapse rate,of ...
Cached Medicine Technology:Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 2Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 3Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 4Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 2Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 3Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 4Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 5
(Date:7/28/2014)... to treat severe chronic migraine headaches led to significant ... in patients treated at Massachusetts General Hospital (MGH). ... Surgery report that more than half of 35 patients ... had headaches associated with compression of craniofacial nerves ... team,s paper has received advance online publication in the ...
(Date:7/28/2014)... Glutamine is the most abundant single amino ... conditionally essential during times when the body undergoes large ... Immune System Support. , Having a heavy work out ... with additional glutamine may be advantageous. Glutamine supplementation may ... digestion and immune system function. Stress on the body ...
(Date:7/28/2014)... 2014 (HealthDay News) --,The more chronic medical conditions people ... may be, a new study claims. Since ... issues, scientists at Johns Hopkins Bloomberg School of Public ... why gains in life expectancy are slowing in the ... as diabetes, kidney disease and heart failure is now ...
(Date:7/28/2014)... divide unless there is enough oxygen present to support ... types circumvent this rule. Researchers at The Johns Hopkins ... cells, warning signals, enabling cancers to continue to divide ... the researchers found that lysosomes the cell,s protein ... also uncovered new evidence that certain drugs can halt ...
(Date:7/28/2014)... NY (PRWEB) July 28, 2014 The ... organization that has donated more than 200,000 books to ... 2001, announces the launch of Brooke’s Cooks, a new ... while encouraging healthy living among at-risk children and their ... will include a series of nutrition information workshops, cooking ...
Breaking Medicine News(10 mins):Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Cell's recycling center implicated in division decisions 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4
... 3 Endologix, Inc. (Nasdaq: ELGX ), developer of minimally ... and Chief Executive Officer, is scheduled to present at three upcoming ... Adams 3rd Annual Cardiovascular Conference at the Nikko Hotel in San ... Event: Canaccord Adams 3rd Annual Cardiovascular Conference, ...
... after the attacks, study shows , TUESDAY, Nov. 3 (HealthDay ... asthma rates twice that of the general population, a new ... and volunteers who had spent time at Ground Zero reported ... about 4 percent of the general population. The rate of ...
... , TUESDAY, Nov. 3 (HealthDay News) -- Experts have ... healthier than regular cigarettes, and new research suggests they ... less likely to quit, even those who switch specifically ... "switching to [,light, cigarettes] for any reason ...
... NBTY, Inc. (NYSE: NTY ) ( www.NBTY.com ... announced it will web cast a conference call to review fiscal ... ), on Monday, November 9, 2009 at 4:30 PM (ET). ... results will be issued at 4:00 PM (ET) that day. , ...
... COLUMBUS, Ohio, Nov. 3 National claims and risk management ... approach to claims management that ensures medical experts are involved ... company notes that the goal of the new service is ... the duration and overall cost of workers, comp claims. Avizent ...
... ... of the Health IT Standards Committee hearing held in Washington, D.C. last week, which was ... ... Orion Health Inc. endorses and commends the efforts of the Health IT Standards Committee ...
Cached Medicine News:Health News:Endologix to Present at Three Upcoming Conferences 2Health News:World Trade Center Workers Twice as Likely to Have Asthma 2Health News:World Trade Center Workers Twice as Likely to Have Asthma 3Health News:Switch to 'Light' Cigarettes Makes Quitting Tougher 2Health News:Switch to 'Light' Cigarettes Makes Quitting Tougher 3Health News:NBTY to Web Cast Fiscal Fourth Quarter Conference Call 2Health News:Avizent's New TeamCOMP Approach Helps Ensure Lower Workers' Comp Costs and Faster Claims Resolution 2Health News:Orion Health&#8482; Participates in Health IT Standards Committee Hearing 2Health News:Orion Health&#8482; Participates in Health IT Standards Committee Hearing 3Health News:Orion Health&#8482; Participates in Health IT Standards Committee Hearing 4
... The StatusFirst CHF test ... anti-NT-proBNP antibody/streptavidin solid-phase chromatographic ... a sample has been ... well, the StatusFirst CHF ...
... practices that need an ... Burdick Vision,Premier Holter System ... The Vision Premier system,adds ... a,more comprehensive list of ...
... EK-10 single-channel,electrocardiograph features a ... keypad. It provides the,necessary ... quick and,accurate diagnosis. The ... a built in handle ...
... contrast levels (high, 9.5 % and 6%) of ... is designed to detect very subtle changes in ... or due to refractive surgery. The upper two ... and acuity levels as the lower two rows; ...
Medicine Products: